Zydus Lifesciences Limited today announced the successful completion of its tender offer for the acquisition of Assertio Holdings Inc, marking a significant step in the company’s strategy to expand its footprint in the United States pharmaceutical market. The acquisition was completed through Zara Merger Sub Inc, a wholly owned subsidiary of Zydus Lifesciences. Under the terms of the transaction, shareholders of Assertio received a cash consideration of US$23.50 per share, subject to applicable tax withholdings.
At the expiration of the tender offer on June 15, 2026, more than 4.28 million shares of Assertio common stock had been validly tendered and not withdrawn, representing approximately 66.3 per cent of the company’s outstanding shares. The tender threshold enabled Zydus to move forward with the next stage of the transaction and complete the acquisition process.
The company confirmed that all tendered shares have been accepted for payment in accordance with the offer terms and that the merger process is expected to be finalized immediately thereafter. Following completion of the merger, all remaining outstanding shares not tendered during the offer period will be converted into the right to receive the same cash consideration of US$23.50 per share.
As a result of the transaction, Assertio will become a wholly owned subsidiary of Zydus Lifesciences. The company’s common stock will cease trading on the Nasdaq Global Market and will be delisted following completion of the merger process.
The acquisition represents an important milestone in Zydus Lifesciences’ international growth strategy. By integrating Assertio’s portfolio and commercial capabilities, the company aims to strengthen its position in key therapeutic segments while expanding access to healthcare solutions in one of the world’s largest pharmaceutical markets.
Zydus Lifesciences has continued to invest in innovation, research and global expansion as part of its long-term vision of delivering differentiated healthcare products across multiple geographies. The company operates across the pharmaceutical value chain, from discovery and development to manufacturing and commercialization, serving patients in numerous markets worldwide.
With a workforce of more than 29,000 employees, including over 1,500 research scientists, Zydus remains focused on advancing science-driven healthcare solutions that improve patient outcomes and enhance access to quality medicines. The acquisition of Assertio is expected to further strengthen the company’s commercial platform and support its ambition to build a larger global presence in specialty and branded healthcare segments.
